JB

J B Chemicals & Pharmaceuticals Ltd

Q4 FY26Pharmaceuticals & Biotechnology

J B Chemicals & Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹904Cr
−4.7% YoY
−15.1% QoQ
Net profit
₹101Cr
−30.8% YoY
−49% QoQ
Margin
22%
−2 pp YoY
−6 pp QoQ

What the Q4 FY26 call signalled

1 of 2 strong

RevenueModerate growth
MarginMargins slightly up
Price₹2,409
Market cap₹38.7K Cr
P/E53.8

The short version

JB Chemicals aims for gradual recovery to previous growth trajectories post Q4 operational reset. JB Chemicals expects gradual normalization and recovery in growth starting Q1 FY27, post Q4 operational reset.

From J B Chemicals & Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Moderate growth
  • JB Chemicals aims for gradual recovery to previous growth trajectories post Q4 operational reset.
  • India business expected to achieve double-digit (low to mid-teens) growth, likely taking a couple of quarters to normalize.
  • International business anticipates single-digit growth starting Q2 FY27, factoring in geopolitical challenges.
  • CDMO segment has strong growth drivers with multiple signed contracts but faces execution delays; growth momentum expected once execution improves.
  • Growth strategies include increasing wallet share with existing top customers (Innova, Kenvue, P&G, Reckitt), expanding geographic footprint, and tapping new large customers globally.
  • Merger synergies with Torrent Pharma expected to drive growth in branded business and improve margins.

2 more points from J B Chemicals & Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what J B Chemicals & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what J B Chemicals & Pharmaceuticals Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what J B Chemicals & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • JB Chemicals and Pharma has several new contracts and projects signed in the CDMO segment with top global customers like Innova, Kenvue, P&G, and Reckitt.
  • The company aims to accelerate execution and delivery of these signed contracts to convert them into revenue faster.
  • Growth strategy includes increasing wallet share with existing customers by expanding geographic footprint, supplying existing products in additional markets.

2 more points from J B Chemicals & Pharmaceuticals Ltd's call on order book

Create a free account to keep reading this call

J B Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

J B Chemicals & Pharmaceuticals Ltd Q4 FY26 results — key figures

J B Chemicals & Pharmaceuticals Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue904949-4.7%1,065-15.1%
Operating profit (EBITDA)201226-11.1%296-32.1%
Operating margin22%24%-2 pp28%-6 pp
Profit before tax135193-30.1%267-49.4%
Net profit (PAT)101146-30.8%198-49%
EPS (₹)6.319.36-32.6%12.63-50%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹904 Cr, net profit ₹101 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

J B Chemicals & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were J B Chemicals & Pharmaceuticals Ltd Q4 FY26 results?

JB Chemicals aims for gradual recovery to previous growth trajectories post Q4 operational reset. JB Chemicals expects gradual normalization and recovery in growth starting Q1 FY27, post Q4 operational reset.

What is J B Chemicals & Pharmaceuticals Ltd share price analysis?

J B Chemicals & Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 53.8 with a market cap of ₹38,677 Cr. Investors should review the full earnings analysis for detailed insights.

Keep J B Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.